Bioventus Director Martin Sutter's Equity Transactions and Holdings

This Form 4 filing reports equity transactions by Martin P. Sutter, a director and 10% owner of Bioventus Inc., covering the period June 2-3, 2026. Sutter received 32,282 shares of Class A Common Stock on June 2 through the vesting of restricted stock units (RSUs) that converted to common stock. The following day, he was granted 25,146 new RSUs that will vest based on board service continuity and the company's next annual meeting. Sutter holds both direct and indirect ownership positions, including direct ownership of 117,523 shares and indirect beneficial ownership of 13,021,324 shares through investment entities where he serves as a manager. The filing details the vesting schedule and ownership structure of his equity holdings in the medical technology company.